November 9, 2005 -- Prana soared after its Alzheimers drug met its Phase I endpoints; Chemokine Therapeutics released positive data from a pre-clinical test prostate cancer treatment; Cell Therapeutics said a Phase III trial showed Pixantron added to the efficacy of Rituxan; Bioenvision reported that clofarabine increased the response in leukemia patients; Amgen filed a patent suit against Roche over its anemia drug Epogen; AstraZeneca took Teva to court over patent rights for Seroquel; CombinatoRx cuts the expected price range on its IPO; Molecular Insight filed for its initial public offering; and Serono confirmed it has discussed a merger with four major pharma partners. The Centient Biotech 200™ held on to a small gain, closing with up 4 points at 3871.67, an increase of .11%.
